Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain
Abstract Aims/Introduction Diabetic peripheral neuropathic pain (DPNP) affects the functionality, mood and sleep patterns of patients with diabetes. Mirogabalin, an α2δ ligand with a slower dissociation for α2δ‐1 versus α2δ‐2 subunits, showed efficacy and safety in a randomized, double‐blind, placeb...
Main Authors: | Masayuki Baba, Norimitsu Matsui, Masanori Kuroha, Yosuke Wasaki, Shoichi Ohwada |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-05-01
|
Series: | Journal of Diabetes Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1111/jdi.13178 |
Similar Items
-
Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled phase III study in Asian patients
by: Masayuki Baba, et al.
Published: (2019-09-01) -
Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study
by: Masayuki Baba, et al.
Published: (2020-02-01) -
Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study
by: Tomoko Tetsunaga, et al.
Published: (2020-05-01) -
Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week Study
by: Baba M, et al.
Published: (2020-07-01) -
Frequency of Adverse Drug Reactions and Analgesic Effects of Mirogabalin during Treatment of Peripheral Neuropathic Pain: A Retrospective Clinical Investigation
by: Kazuhide Inage, et al.
Published: (2020-10-01)